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COVID-19 during pregnancy and preeclampsia is an independent asso-
ciation or if these are caused by common risk factors.
OBJECTIVE: This study aimed to quantify any independent association
between COVID-19 during pregnancy and preeclampsia and to determine the
effect of these variables on maternal and neonatal morbidity and mortality.
STUDY DESIGN: This was a large, longitudinal, prospective, unmatched
diagnosed and not-diagnosed observational study assessing the effect of
COVID-19 during pregnancy on mothers and neonates. Two consecutive not-
diagnosed women were concomitantly enrolled immediately after each diag-
nosed womanwas identified, at any stage during pregnancy or delivery, and at
the same level of care to minimize bias. Women and neonates were followed
until hospital discharge using the standardized INTERGROWTH-21st protocols
and electronic data management system. A total of 43 institutions in 18
countries contributed to the study sample. The independent association be-
tween the 2 entities was quantifiedwith the risk factors known to be associated
with preeclampsia analyzed in each group. The outcomes were compared
among women with COVID-19 alone, preeclampsia alone, both conditions,
and those without either of the 2 conditions.
RESULTS: We enrolled 2184 pregnant women; of these, 725 (33.2%) were
enrolled in the COVID-19 diagnosed and 1459 (66.8%) in the COVID-19 not-
diagnosed groups. Of these women, 123 had preeclampsia of which 59 of 725
(8.1%) were in the COVID-19 diagnosed group and 64 of 1459 (4.4%) were in
the not-diagnosed group (risk ratio, 1.86; 95%confidence interval, 1.32e2.61).
After adjustment for sociodemographic factors and conditions associated with
both COVID-19 and preeclampsia, the risk ratio for preeclampsia remained
significant among all women (risk ratio, 1.77; 95% confidence interval,
1.25e2.52) and nulliparous women specifically (risk ratio, 1.89; 95% confi-
dence interval, 1.17e3.05). There was a trend but no statistical significanceCite this article as: Papageorghiou AT, Deruelle P,
Gunier RB, et al. Preeclampsia and COVID-19: results
from the INTERCOVID prospective longitudinal study. Am
J Obstet Gyneco 2021;225:289.e1-17.
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https://doi.org/10.1016/j.ajog.2021.05.014The risk ratio for preterm birth for all women diagnosed with COVID-19 and
preeclampsia was 4.05 (95% confidence interval, 2.99e5.49) and 6.26 (95%
confidence interval, 4.35e9.00) for nulliparous women. Comparedwith women
with neither condition diagnosed, the composite adverse perinatal outcome
showed a stepwise increase in the risk ratio for COVID-19without preeclampsia,
preeclampsia without COVID-19, and COVID-19 with preeclampsia (risk ratio,
2.16; 95% confidence interval, 1.63e2.86; risk ratio, 2.53; 95% confidence
interval, 1.44e4.45; and risk ratio, 2.84; 95% confidence interval, 1.67e4.82,
respectively). Similar findings were found for the composite adverse maternal
outcome with risk ratios of 1.76 (95% confidence interval, 1.32e2.35), 2.07
(95% confidence interval, 1.20e3.57), and 2.77 (95% confidence interval,
1.66e4.63). The association between COVID-19 and gestational hypertension
and the direction of the effects on preterm birth and adverse perinatal and
maternal outcomes, were similar to preeclampsia, but confined to nulliparous
women with lower risk ratios.
CONCLUSION: COVID-19 during pregnancy is strongly associated with
preeclampsia, especially among nulliparous women. This association is in-
dependent of any risk factors and preexisting conditions. COVID-19 severity
does not seem to be a factor in this association. Both conditions are associated
independently of and in an additive fashion with preterm birth, severe perinatal
morbidity and mortality, and adverse maternal outcomes. Women with pre-
eclampsia should be considered a particularly vulnerable group with regard to
the risks posed by COVID-19.
Key words: aspirin, cohort, gestational hypertension, hypertension, hy-
pertensive disorders in pregnancy, infection, morbidity, mortality, obesity,
overweight, preeclampsia, pregnancy, preterm birth, proteinuria, relative
risk, renal disease, risk ratio, SARS-CoV 2, small for gestational ageIntroduction
COVID-19, which is primarily a respira-
tory infection, can have marked
multiorgan, vascular effects leading to
hypertension, renal disease, thrombocy-
topenia, and hepatic injury. SARS-CoV-2
can produce direct endothelial damage,
thromboinflammation, dysregulation ofSEPTEMBER 2021 Ameriimmune responses, and alterations in
angiotensin-converting enzyme 2e
related pathways.1 Preeclampsia, but
not gestational hypertension (GH),
causes endothelial damage, placental
oxidative stress, and an antiangiogenic
state leading to hypertension and
proteinuria,2 and similar multiorgancan Journal of Obstetrics & Gynecology 289.e1
AJOG at a Glance
Why was this study conducted?
It is unclear whether the suggested association between COVID-19 during
pregnancy and preeclampsia is independent of common risk factors. This study
aimed to quantify any independent association between COVID-19 during
pregnancy and preeclampsia and to determine key related pregnancy outcomes
and maternal and neonatal morbidity and mortality.
Key findings
After adjusting for risk factors, COVID-19 during pregnancy is independently
associated with preeclampsia (risk ratio [RR), 1.77; 95% confidence interval [CI),
1.25e2.52 in all women, and RR, 1.89; 95% CI, 1.17e3.05 in nulliparous women)
and, to a lesser degree, with gestational hypertension (RR, 1.53; 95% CI, 1.11
e2.11). COVID-19 and preeclampsia are associated independently of and in an
additive fashion with an increased risk for preterm birth (RR, 4.05; 95 % CI, 2.99
e5.49), small for gestational age neonates (RR, 2.32; 95% CI, 1.50e3.58), severe
perinatal morbidity and mortality (RR, 2.84; 95% CI, 1.67e4.82), and composite
maternal morbidity and mortality (RR, 2.51; 95% CI, 1.72e3.67).
What does this add to what is known?
Women with preeclampsia should be considered a particularly vulnerable group
for COVID-19.
Original Research OBSTETRICS ajog.orgeffects as seen in severe cases of
COVID-19.3
Because COVID-19 has been shown
to increase the risk for adverse pregnancy
outcomes, including preeclampsia,4e6
the concept of a COVID-19eassociated
preeclampsia-like syndrome, which in-
cludes similar placental pathology, has
been proposed.7e9 However, it is
important to note that COVID-19 dur-
ing pregnancy and preeclampsia share
the same set of risk factors, namely
preexisting hypertension, obesity, and
diabetes.10e12 Thus, the association be-
tween COVID-19 and preeclampsia
could be confounded by common un-
derlying risk factors.
A genuine association could manifest
in the following 3 ways: (1) COVID-19
could cause symptoms and signs that
meet the diagnostic criteria for pre-
eclampsia, although these are separate
conditions; (2) preeclampsia, which has
pathophysiological changes already
apparent early in pregnancy,13e15 could
constitute an additional risk factor for
COVID-19, or (3) COVID-19 could be
on an etiologic pathway toward pre-
eclampsia, which in itself has been
related etiologically to infectious
diseases.16e18289.e2 American Journal of Obstetrics & GynecolIn this secondary analysis of the
INTERCOVID multinational study,19
we explored these possibilities
including the independent association
between the 2 conditions with severe
adverse maternal and neonatal
outcomes.
Materials and Methods
INTERCOVID was a large, longitudinal,
prospective, multinational observational
study assessing the effect of COVID-19
during pregnancy on mothers and neo-
nates.19,20 A total of 43 institutions in
Argentina, Brazil, Egypt, France, Ghana,
India, Indonesia, Italy, Japan, Mexico,
Nigeria, North Macedonia, Pakistan,
Russia, Spain, Switzerland, the United
Kingdom, and the United States
contributed to the study.
Between March 2, 2020, and February
2, 2021, we enrolled women aged 18
years with a diagnosis of COVID-19 at
any stage during their current pregnancy
(diagnosed group) based on (1) a labo-
ratory confirmation of COVID-19 or
radiological pulmonary findings sug-
gestive of COVID-1921 or (2) 2 pre-
defined COVID-19 symptoms. Of note,
2 immediately concomitant pregnant
women aged 18 years without any ofogy SEPTEMBER 2021these diagnostic criteria (not-diagnosed
group) were enrolled for each diagnosed
woman to create an unbiased sample
representative of all not-diagnosed
pregnant women in these institutions.
Women in the diagnosed and not-
diagnosed samples were followed until
hospital discharge of the newborn.
When a woman was diagnosed ante-
natally, 2 not-diagnosed women of a
similar gestational age (2 weeks),
receiving standard antenatal care, were
enrolled that day. If not possible or if
those not-diagnosed women were lost to
follow-up, we enrolled 2 not-diagnosed
women who delivered immediately af-
ter the diagnosed woman. The same se-
lection strategy was employed when a
diagnosed woman was identified at
hospital admission and delivery was
likely to occur during that admission. If a
not-diagnosed woman declined partici-
pation, the next woman was approached
until 2 not-diagnosed women were
enrolled for each diagnosed case. We
sought confirmation from a biweekly,
random 10% sample that the 2 not-
diagnosed women were appropriately
chosen; we excluded 5 diagnosed women
and the corresponding not-diagnosed
women without such confirmation.
Live and stillborn and singleton and
multiple gestation pregnancies in addi-
tion to those with congenital anomalies
were included.
For the secondary analysis, we
considered preeclampsia as a primary
co-exposure in addition to COVID-19
status; GH was considered a secondary
co-exposure. Preeclampsia was defined
by (1) blood pressure of 140/90 mm Hg
or greater or an increase of 30 mm Hg
systolic or 15 mm Hg diastolic above
baseline values on at least 2 occasions 6
hours or more apart with proteinuria
that developed after 20 weeks’ gestation
in a previously normotensive pregnancy;
or (2) blood pressures of 160 mm Hg
systolic or 110 mm Hg diastolic on 2
occasions, at least 4 hours but not more
than 168 hours apart, or if the first
measurement was immediately followed
by treatment with an antihypertensive,
either of these scenarios being associated
with the presence of proteinuria; (3)
eclampsia, defined as the occurrence of
ajog.org OBSTETRICS Original Researchconvulsions or coma unrelated to cere-
bral conditions in a woman with symp-
toms and signs of preeclampsia; or (4)
evidence of hemolysis, elevated liver
enzymes, and low platelet count syn-
drome. GH was defined as blood pres-
sure of >140/90 mm Hg without
proteinuria after 20 weeks’ gestation in a
previously normotensive woman.
Outcomes
The neonatal outcomes of interest were
preterm birth (<37 weeks’ gestation),
frequency of small for gestational age
(SGA) neonates (birthweight below the
10th percentile for gestational age and
sex according to the INTERGROWTH-
21st Newborn Size Standards),22 and an
unweighted index, namely the severe
perinatal morbidity and mortality index,
which includes (1) fetal death; or (2) at
least 1 of the following severe compli-
cations: bronchopulmonary dysplasia,
hypoxic-ischemic encephalopathy,
sepsis, anemia requiring transfusion,
patent ductus arteriosus requiring
treatment or surgery, intraventricular
hemorrhage, necrotizing enterocolitis or
retinopathy of prematurity diagnosed
before hospital discharge; or (3) admis-
sion to the neonatal intensive care unit
for7 days; or (4) neonatal death before
hospital discharge. We also examined a
composite adverse maternal outcome,
defined as the presence of (1) at least 1 of
the following pregnancy-related morbid-
ities: vaginal bleeding during pregnancy,
preterm labor, and infection requiring
antibiotics; or (2) any other pregnancy-
related conditions requiring treatment
or referral; or (3) maternal admission to
the intensive care unit (ICU) or referral to
a higher level of care; or (4) death.
Gestational age at delivery was esti-
mated based on the earliest ultrasound
scan (<14 weeks’ gestation using the
international INTERGROWTH-21st
standards).23 If early ultrasound dating
was not carried out, the best obstetrical
estimate was used based on all clinical
and ultrasound data available.24
Data management and analysis
We used the same centrally coordinated
data management system developed for
the INTERGROWTH-21st Project(MedSciNet, London, United
Kingdom).25 All data were entered
locally into the on-line system with its
extensive, built-in quality control facil-
ity. Queries can be dispatched immedi-
ately to the study sites, which provides
continuously clean datasets for inter-
mediate analysis.
Statistical methodology
We first compared the baseline de-
mographic characteristics, and gyneco-
logic, obstetrical, and medical histories
of the 4 study groups, namely COVID-
19 diagnosis without preeclampsia, pre-
eclampsia without COVID-19, COVID-
19 diagnosis with preeclampsia, and
neither condition diagnosed. Second, we
explored the association between pre-
eclampsia and COVID-19 by adjusting
for potential confounders that were
selected a priori to be on the casual
pathway using a directed acyclic graph.
We further considered effect modifica-
tion by parity or aspirin use during
pregnancy and performed sensitivity
analyses of multiple pregnancies and age
of <20 years and, for the main outcome
of COVID-19 and preeclampsia, adjust-
ment by study site as a covariate and
using mixed-effects models with
random slopes by site.
Associations of preeclampsia and
COVID-19 with the binary outcomes
were assessed using generalized linear
models with a Poisson distribution and
log link function. Estimates are expressed
as risk ratios (RRs) and 95% confidence
intervals (CIs). We used robust standard
errors (SEs) to account for model mis-
specification and a clustered estimator of
variance in models with perinatal out-
comes to account for the lack of inde-
pendence of multiple births. We assessed
the joint effects of COVID-19 and pre-
eclampsia on neonatal outcomes using an
interaction term in the models.
In all regression models, we adjusted
first for potential sociodemographic
confounders, such as maternal age, par-
ity, and tobacco use during pregnancy,
and second for a set of risk factors know
to be associated with both COVID-19
and preeclampsia such as overweight
and obesity, a history of diabetes, cardiac
disease, hypertension, or renal disease.SEPTEMBER 2021 AmeriFinally, we adjusted for pregnancy his-
tory that included a preterm birth,
miscarriage, or low birthweight neonate.
We plotted Kaplan-Meier curves with
the percentage of women who remained
pregnant according to the gestational age
to compare the distributions among the
4 groups. We also plotted Kaplan-Meier
curves with the gestational age at the
time of COVID-19 diagnosis as the
dependent variable and the diagnosis of
preeclampsia as the independent binary
variable. Hazard ratios with 95% CIs
were estimated using a Cox proportional
hazards model.26
Ethics approval was obtained from the
Oxford Tropical Research Ethics Com-
mittee (OxTREC), reference 526-20, and
all participating medical institutions
obtained local approval from their cor-
responding ethics committees or insti-
tutional review boards.Written or verbal
consent was obtained according to local
practices. The study was conducted in
accordance with the principles of the
Declaration of Helsinki and the Inter-
national Conference on Harmonization-
Good Clinical Practice guidelines and
did not interfere with the clinical man-
agement of the women enrolled. The
protocol was published on the study
website before starting the study.20
Results
We enrolled a total of 2184 pregnant
women. Of these, 725 were diagnosed
with COVID-19 during pregnancy on the
basis of a laboratory confirmation (real-
time polymerase chain reaction [RT-
PCR) test, n¼672, 92.7%), radiological
confirmation (n¼4, 0.6%), or 2 pre-
defined COVID-19 symptoms (n¼49,
6.8%) if no laboratory results were
available. The remaining 1459 pregnant
women constituted the not-diagnosed
COVID-19 group enrolled concomi-
tantly using the rigorous methodology
described above. In the not-diagnosed
COVID-19 group, 730 of 1459 (50.0%)
women were tested; of these, 698 had a
negative RT-PCR test and 32 had a
negative COVID-19 antibody test.
The contribution to the total study
population ranged from 19.9% (Italy,
n¼434) to 0.1% (Macedonia, n¼3).
The other sites contributed to thecan Journal of Obstetrics & Gynecology 289.e3
TABLE 1
Baseline characteristics among women according to preeclampsia and COVID-19 diagnosis
Demographic and socioeconomic
characteristics











Maternal age (y) 29.57.1 30.76.3 30.06.0 30.36.1
Maternal height (cm) 158.87.3 159.97.1 161.47.6 161.27.9
Maternal weight (kg) 72.123.2 69.717.2 66.814.9 64.915.8
Body mass index (kg/m2) 28.58.5 27.26.0 25.65.4 24.95.7
Married or cohabiting (%) 82.5 85.0 88.2 89.0
University education (%) 19.2 22.6 32.3 33.9
Worked outside the home (%) 39.2 42.6 52.4 51.0
Smoker during index pregnancy (%) 3.4 6.3 2.8 3.7
Alcohol 1 units/wk (%) 0.0 0.0 2.1 2.3
Gynecologic and obstetrical history
Previous pregnancy (%) 62.7 64.1 72.0 66.9
Previous miscarriage (%) 32.2 32.8 31.6 30.9
Previous birth (%) 47.5 50.0 61.3 55.0
Previous baby <2.5 kg or >4.5 kg (%) 11.8 16.1 8.7 7.3
Previous baby <37 wk’s gestation (%) 7.8 14.3 7.1 5.6
Previous stillbirth or neonatal death (%) 5.9 3.6 5.3 3.2
Previous adverse pregnancy outcomea (%) 39.0 45.3 38.9 36.7
Maternal medical history
Diabetes (%) 8.5 3.1 4.2 1.3
Thyroid and other endocrine disease (%) 3.4 4.7 11.4 9.2
Cardiac disease (%) 8.5 1.6 1.2 1.2
Hypertension (%) 22.0 15.6 2.0 1.5
Chronic respiratory disease (%) 3.7 6.5 3.4 2.0
Kidney disease (%) 1.7 4.7 0.6 0.9
Malaria (%) 5.1 0.0 1.2 1.5
Tuberculosis (%) 0.0 0.0 0.5 0.2
2 of the above conditions (%) 10.2 3.1 2.7 1.7
a Includes previous miscarriage, stillbirth or neonatal death, or infant born preterm or at a low birthweight.
Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.
Original Research OBSTETRICS ajog.orgstudy data as follows: Argentina
contributed 10.6% (n¼231), the United
States contributed 10.2% ( n¼222),
Pakistan contributed 9.6% (n¼210),
Mexico contributed 8.0% (n¼
174), France contributed 6.7% (n¼147),
India contributed 6.7% (n¼147), the
United Kingdom contributed 5.3%
(n¼116), Russia contributed 5.0%
(n¼108), Spain contributed 4.7%289.e4 American Journal of Obstetrics & Gynecol(n¼102), Brazil contributed 4.3%(n¼93),
Nigeria contributed 3.6% (n¼
78), Indonesia contributed 2.6% (n¼57),
Ghana contributed 1.7% (n¼36),
Japan contributed 0.6% (n¼12), Egypt
contributed 0.4% (n¼9), and Switzerland
contributed 0.2% (n¼5).
Overall, 123 women had preeclamp-
sia; of these, 8.1% (59 of 725) of the
women were in the COVID-19ogy SEPTEMBER 2021diagnosed group and 4.4% (64 of 1459)
were in the COVID-19 not-diagnosed
group, (RR, 1.77; 95% CI, 1.25e2.52).
There were 143 women with GH; 8.4%
(61 of 725) of the women were in the
COVID-19 diagnosed group and 5.6%
(82 of 1459) were in the COVID-19 not-
diagnosed group (RR, 1.53; 95% CI,
1.11e2.11). Of the 725 women with
COVID-19, 292 (40.3%) were
TABLE 2
Associations between COVID-19 diagnosis and preeclampsia
Adjustments All women (n¼2075) Nulliparous (n¼901) Parous (n¼1174)
Unadjusted
No COVID-19 diagnosis Ref Ref Ref
COVID-19 diagnosis 1.95 (1.38e2.75)a 2.20 (1.37e3.55)a 1.78 (1.08e2.94)a
No COVID-19 diagnosis Ref Ref Ref
COVID-19 diagnosis, asymptomatic 1.82 (1.14e2.91)a 2.23 (1.21e4.12)a 1.46 (0.71e3.02)
COVID-19 diagnosis with symptoms 2.04 (1.37e3.02)a 2.18 (1.24e3.82)a 1.98 (1.14e3.46)a
Demographic adjustment onlyb
No COVID-19 diagnosis Ref Ref Ref
COVID-19 diagnosis 2.00 (1.41e2.83)a 2.14 (1.33e3.44)a 1.75 (1.06e2.88)a
No COVID-19 diagnosis Ref Ref Ref
COVID-19 diagnosis, asymptomatic 1.84 (1.15e2.94)a 2.14 (1.17e3.93)a 1.53 (0.74e3.16)
COVID-19 diagnosis with symptoms 2.11 (1.42e3.14)a 2.14 (1.22e3.76)a 1.88 (1.08e3.27)a
Full modelc
No COVID-19 diagnosis Ref Ref Ref
COVID-19 diagnosis 1.77 (1.25e2.52)a 1.89 (1.17e3.05)a 1.64 (0.99e2.73)d
No COVID-19 diagnosis Ref Ref Ref
COVID-19 diagnosis, asymptomatic 1.70 (1.07e2.72)a 1.99 (1.07e3.71)a 1.46 (0.71e3.00)
COVID-19 diagnosis with symptoms 1.81 (1.22e2.70)a 1.81 (1.04e3.16)a 1.75 (0.99e3.08)d
The total numbers reflect the number of participants with complete outcome and covariate data in the final models.
Ref, reference group.
a P<.05; b Adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, and history of adverse pregnancy outcomes; c Adjusted for maternal age, previous parity
(nulliparous vs parous), tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes, cardiac disease, hypertension, kidney disease, or
adverse pregnancy outcomes; d P<.1.
Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.
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symptomatic; 22 cases of preeclampsia
occurred in the asymptomatic group and
37 cases of preeclampsia occurred in the
symptomatic group.
The baseline demographic character-
istics and gynecologic, obstetrical, and
medical histories across these 4 groups
are shown in Table 1. The median gesta-
tional age at COVID-19 diagnosis was
37.6 (interquartile range, 34.3e39.1)
weeks, and 71.3% of women were diag-
nosed <10 days before giving birth.
Association between COVID-19 and
preeclampsia
Table 2 presents the preeclampsia risk for
the COVID-19 diagnosed and not-
diagnosed groups. After initial adjust-
ment for maternal age, parity (nullipa-
rous vs parous), tobacco use, and historyof adverse pregnancy outcomes, the RR
for preeclampsia remained statistically
significant for nulliparous (RR, 2.14;
95% CI, 1.33e3.44) and parous women
(RR, 1.75; 95%CI, 1.06e2.88), however,
the interaction was not significant
(P¼.60). Further adjustment for condi-
tions known to be associated with pre-
eclampsia (overweight and obesity,
history of diabetes, cardiac disease, hy-
pertension, or renal disease) led to a
relatively small reduction in the RR,
which remained statistically significant
for nulliparous women (RR, 1.89; 95%
CI, 1.17e3.05) (Table 2). These results
strongly suggest that the association be-
tween COVID-19 and preeclampsia is
independent of the main confounding
variables. The results were also very
similar after adjusting for study site
(Supplemental Table 3).SEPTEMBER 2021 AmeriAspirin was used by 9.6% of women,
but no evidence of effect modification by
aspirin use was seen (P value for inter-
action, .42 for the model adjusting for
demographic and risk factors). Sensi-
tivity analyses excluding subgroups of
womenwith maternal age<20 years and
those with multiple pregnancy did not
change the results. Similarly, a sensitivity
analysis that excluded women diagnosed
early in the pandemic based on 2 or
more symptoms (n¼54), led to a small
reduction in the association (for all
women: from RR, 1.77; 95% CI,
1.25e2.52; to RR, 1.57; 95% CI,
1.08e2.28 and for nulliparous women
from RR, 1.89; 95% CI, 1.17e3.05; to
RR, 1.76; 95% CI, 1.06e2.90).
We explored 5 characteristics to better
understand the association. First, as
described above, the effect was mostlycan Journal of Obstetrics & Gynecology 289.e5
TABLE 3
Association between COVID-19 and preeclampsia according to time elapsed between COVID-19 diagnosis and birth
Time between COVID-19 diagnosis and birth n (%) All women Nulliparous Parous
Unadjusted
No COVID-19 diagnosis 1402 (68.1) Ref Ref Ref
COVID-19 diagnosis, within 7 d of birth or postnatally 426 (20.7) 2.28 (1.57e3.32)a 2.51 (1.51e4.18)a 2.10 (1.21e3.62)a
COVID-19 diagnosis 7 d before birth 232 (11.3) 1.07 (0.57e2.01) 0.96 (0.35e2.66) 1.20 (0.54e2.68)
Adjustedb
No COVID-19 diagnosis 1402 (68.1) Ref Ref Ref
COVID-19 diagnosis, within 7 d of birth or postnatally 426 (20.7) 2.12 (1.44e3.11)a 2.36 (1.40e3.98)a 1.83 (1.04e3.21)a
COVID-19 diagnosis 7 d before birth 232 (11.3) 0.99 (0.55e1.79) 0.74 (0.31e1.80) 1.21 (0.55e2.66)
The total numbers reflect the number of participants with complete outcome and covariate data in the final models.
Ref, reference group.
a P<.05; b Adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes,
cardiac disease, hypertension, kidney disease, or history of adverse pregnancy outcomes.
Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.
Original Research OBSTETRICS ajog.orgobserved among nulliparous women (a
main feature of preeclampsia). Second,
there was no evidence of a biologically or
clinically substantive difference in theFIGURE 1
Kaplan-Meier curves
For gestational age at diagnosis of COVID-19, stra
Blue represents no preeclampsia; red represents p
CI, 1.12e1.97). One woman was diagnosed with
diagnosed from >13 to 26 weeks’ gestation; 63
35 women the information about the gestational a
Papageorghiou et al. Preeclampsia and COVID-19. Am J Obste
289.e6 American Journal of Obstetrics & Gynecolstrength of the association regardless of
whether the women had COVID-19
symptoms or not (RR, 1.81; 95% CI,
1.22e2.70 and RR, 1.70; 95% CI,tified by preeclampsia status during pregnancy.
reeclampsia. Cox model hazard ratio, 1.49 (95%
COVID-19 at 13 weeks’ gestation; 34 were
6 were diagnosed at >26 weeks’ gestation; for
ge at diagnosis was not available.
t Gynecol 2021.
ogy SEPTEMBER 20211.07e2.72 for symptomatic and asymp-
tomatic affected women, respectively)
(Table 2). Hence, COVID-19 severity
was not a factor in the observed associ-
ation (Table 2) when assuming that
symptom occurrence is indicative of
worse disease.
Third, there was no association
among women (32.5%) in whom
COVID-19 was diagnosed>7 days from
delivery (RR, 0.99; 95% CI, 0.55e1.79)
(Table 3), suggesting that the indepen-
dent associationmostly relates towomen
who may have developed preeclampsia
already by the time of their COVID-19
diagnosis (RR, 2.12; 95% CI,
1.44e3.11), particularly among nullip-
arous women (RR, 2.36; 95% CI,
1.40e3.98) (Table 3).
Fourth, as seen in Figure 1, there was a
gradual and constant increase in
COVID-19 diagnoses across gestational
age among women without preeclamp-
sia, whereas women with preeclampsia
were mostly diagnosed with COVID-19
from 33 to 37 weeks’ gestation; there-
after, both curves remained parallel (Cox
model hazard ratio, 1.49; 95% CI,
1.12e1.97 for COVID-19 among
women with preeclampsia).
Finally (Table 4), there was a statisti-
cally significant association between
COVID-19 and GH (RR, 1.53; 95%CI,
1.11e2.11) mostly seen among
TABLE 4
Associations between COVID-19 diagnosis and hypertensive disorders in pregnancya
COVID-19 diagnosis according to parity
Hypertensive disorders in pregnancyb
(n¼266) Gestational hypertension (n¼143)
Unadjusted Adjusted Unadjusted Adjusted
All mothers
No COVID-19 diagnosis Ref Ref Ref Ref
COVID-19 diagnosis 1.67 (1.32e2.12)c 1.56 (1.23e1.98)c 1.61 (1.17e2.22)c 1.53 (1.11e2.11)c
Nulliparous
No COVID-19 diagnosis Ref Ref Ref Ref
COVID-19 diagnosis 2.09 (1.50e2.91)c 1.80 (1.28e2.52)c 2.09 (1.33e3.29)c 1.79 (1.13e2.85)c
Parous
No COVID-19 diagnosis Ref Ref Ref Ref
COVID-19 diagnosis 1.38 (0.98e1.95)d 1.36 (0.97e1.91)d 1.29 (0.82e2.03) 1.32 (0.84e2.06)
The total numbers reflect the number of participants with complete outcome and covariate data in the final models.
Ref, reference group.
a Adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes, cardiac
disease, hypertension, kidney disease, or adverse pregnancy outcomes; b Includes preeclampsia or gestational hypertension; c P<.05; d P<.1.
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1.13e2.85) (Table 4).
Impact of COVID-19 and
preeclampsia on the outcomes
As we have previously shown,19 the
COVID-19 group had an almost 2-fold
higher risk for preterm birth, even after
adjusting for a previous preterm birth. In
Figure 2, A, we show that there was an
additional negative effect of preeclamp-
sia, namely womenwith both conditions
had a RR for preterm birth of more than
4 (above 6 for nulliparous women)
(Table 5). In women with COVID-19
and preeclampsia, 97% of the preterm
births were medically indicated, similar
to the 93% in those with preeclampsia
without COVID-19. However, 80% were
medically indicated in those with
COVID-19 without preeclampsia and
61% were medically indicated in those
with neither condition (Figure 2, B).
The SGA rate was 29.3% in women
with COVID-19 and preeclampsia with
an RR of 2.32 (95%CI, 1.50e3.58) when
compared with the group with neither
condition. The rate in those with pre-
eclampsia without COVID-19 was
17.5%; however, COVID-19 without
preeclampsia was not associated withSGA (11.6%), suggesting that pre-
eclampsia was affecting fetal growth
before COVID-19 infection.
The RR for the severe perinatal
morbidity and mortality index increased
stepwise, particularly among nulliparous
women; the RRs were 2.41 (95% CI,
1.54e3.77), 3.22 (95% CI, 1.51e6.88),
and 3.88 (95% CI, 1.89e7.96) for
women with COVID-19 without pre-
eclampsia, preeclampsia without
COVID-19, and COVID-19 with pre-
eclampsia, respectively (Table 5; unad-
justed results are given in Supplemental
Table 1). Similar results were observed
in those 3 groups for the composite
adverse maternal outcome; the RRs were
1.76 (95%CI, 1.32e2.35), 2.07 (95%CI,
1.20e3.57), and 2.77 (95% CI,
1.66e4.63), respectively. However, we
did not observe a significant interaction
between COVID-19 exposure and pre-
eclampsia on these neonatal outcomes.
Overall, the direction of the effects of
GH on preterm birth (Supplemental
Figure), SGA, the severe perinatal
morbidity and mortality index, and
composite adverse maternal outcome
(Table 6; unadjusted results are given in
Supplemental Table 2) were similar to
what was observed for preeclampsia andSEPTEMBER 2021 Ameriwere confined to nulliparous women,
albeit with lower RRs. There was also a
stepwise increase in the risk for preterm
birth among women with COVID-19
without GH, women with GH without




COVID-19 during pregnancy and pre-
eclampsia are strongly associated with
each other, especially among nulliparous
women. This association is independent
of risk factors and preexisting condi-
tions. COVID-19 severity does not affect
the association. In an additive fashion,
these conditions increase the risks for
preterm birth, severe perinatal
morbidity and mortality, and adverse
maternal outcomes. An effect on SGA
frequency was seen only among women
with preeclampsia.
Hypothesized mechanism of action
and further research
COVID-19 and preeclampsia share
many common risk factors such as
obesity and underlying hypertension. Is
it possible that these explain the
observed association by a process ofcan Journal of Obstetrics & Gynecology 289.e7
FIGURE 2
Kaplan-Meier curves
A, For gestational age at delivery, stratified by preeclampsia and COVID-19 diagnosis and (B) for gestational age at spontaneous birth, treating medically-
indicated births as censored; the spontaneous preterm birth rate was 4.4%. Blue represents no preeclampsia and no COVID-19 diagnosis; red represents
no preeclampsia with a COVID-19 diagnosis; green represents preeclampsia without a COVID-19 diagnosis; orange represents preeclampsia with a
COVID-19 diagnosis.
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interaction or causal relationship?
There is certainly evidence emerging
in support of a biological explanation.
COVID-19 causes endothelial dysfunc-
tion either directly or indirectly, leading
to hyperinflammation and aberrant
antiviral responses.27,28 In addition,
coagulopathy and disseminated intra-
vascular coagulationelike massive
intravascular clot formation are seen in
the most severely ill, nonpregnant pa-
tients.29 During pregnancy, COVID-19
induces specific vascular pathology that
is similar to the changes seen in pre-
eclampsia. In fact, Mendoza et al7 have
introduced the concept of a “pre-
eclampsia-like syndrome” associated
with COVID-19. In other words, it may
be difficult to clinically distinguish this
syndrome from “true” preeclampsia
because they both share characteristics
of the severe endothelial dysfunction
seen in nonpregnant patients.7,30
However, 2 observations from our
study discourage this line of thinking.
The first is that the severity of COVID-19
symptoms did not increase the associa-
tion with preeclampsia, although we
acknowledge that, in a recent cohort289.e8 American Journal of Obstetrics & Gynecolstudy, hypertensive disorders in preg-
nancy were more frequent in those
women with severe COVID-19.31 Sec-
ondly, the association was also present
with GH, a hypertensive condition that
does not present with the “preeclampsia-
like syndrome.”
We believe that the most likely expla-
nation for the observed association is
that preeclampsia and GH are vascular
conditions, preceding infection with
SARS-CoV-2, which increase the risk for
COVID-19 in the same way essential
hypertension does. This is supported by
the relationship being mostly seen in
nulliparous women; if COVID-19 led to
preeclampsia (rather than the other way
round), the association should also have
been seen in parous women. Further-
more, the risk was highest when
COVID-19 was diagnosed in the last 7
days of pregnancy; if COVID-19 were on
the etiologic pathway, an earlier diag-
nosis would likely have had a stronger
association with preeclampsia. The same
conclusion emerges from Figure 1,
namely there was a sharp increase in
COVID-19 diagnoses among women
with preeclampsia between 33 to 37
weeks’ gestation when the conditionogy SEPTEMBER 2021typically manifests itself clinically.
Conversely, in women without pre-
eclampsia, COVID-19 diagnoses were
proportionally distributed throughout
pregnancy. Lastly, the excess risk for
preeclampsia in women with COVID-19
persisted (RR, 1.77; 95% CI, 1.25e2.52)
even when we controlled for maternal
sociodemographic and risk factors for
preeclampsia.
Clinical implications
COVID-19 during pregnancy is known
to increase severe maternal morbidity
and death, particularly respiratory
dysfunction requiring invasive mechan-
ical ventilation or admission to the
ICU.32 Our data provide additional in-
formation about the additive negative
effects of COVID-19 and preeclampsia
during pregnancy. Women who are at
high risk for preeclampsia should also be
considered at higher risk for COVID-19
and should be included in all preventive
strategies during the pandemic.Whether
aspirin administration reduces this risk
further is not known, but effect modifi-
cation by aspirin treatment in our study
did not show any changes to the strength
of the association.
TABLE 5
Associations between preeclampsia and COVID-19 diagnosis with adverse pregnancy and neonatal outcomesa
Outcomes
n (%) with the
outcome All women Nulliparous Parous
Preterm birth
No preeclampsia, no COVID-19 diagnosis 163 (12.2) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 119 (19.6) 1.57 (1.27e1.95)b 1.66 (1.16e2.38)b 1.50 (1.14e1.96)b
Preeclampsia, no COVID-19 diagnosis 28 (45.2) 3.48 (2.54e4.76)b 4.14 (2.72e6.30)b 2.49 (1.58e3.93)b
Preeclampsia, with COVID-19 diagnosis 33 (56.9) 4.05 (2.99e5.49)b 6.26 (4.35e9.00)b 3.01 (1.92e4.72)b
Small for gestational age
No preeclampsia, no COVID-19 diagnosis 162 (12.6) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 69 (11.6) 0.98 (0.75e1.28) 1.17 (0.83e1.65) 0.77 (0.50e1.16)
Preeclampsia, no COVID-19 diagnosis 11 (17.5) 1.48 (0.80e2.71) 1.65 (0.81e3.34) 0.98 (0.33e2.88)
Preeclampsia, with COVID-19 diagnosis 17 (29.3) 2.32 (1.50e3.58)b 2.61 (1.55e4.40)b 2.33 (1.06e5.13)b
Severe perinatal morbidity and mortality indexc
No preeclampsia, no COVID-19 diagnosis 100 (7.3) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 100 (15.9) 2.16 (1.63e2.86)b 2.41 (1.54e3.77)b 1.91 (1.33e2.74)b
Preeclampsia, no COVID-19 diagnosis 15 (22.4) 2.53 (1.44e4.45)b 3.22 (1.51e6.88)b 1.76 (0.77e4.02)
Preeclampsia, with COVID-19 diagnosis 16 (27.1) 2.84 (1.67e4.82)b 3.88 (1.89e7.96)b 2.25 (1.06e4.80)b
Composite maternal morbidity and mortality indexd
No preeclampsia, no COVID-19 diagnosis 188 (14.1) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 157 (25.8) 1.84 (1.52e2.22)b 1.76 (1.32e2.35)b 1.85 (1.45e2.38)b
Preeclampsia, no COVID-19 diagnosis 16 (25.8) 1.74 (1.11e2.71)b 2.07 (1.20e3.57)b 1.31 (0.62e2.77)
Preeclampsia, with COVID-19 diagnosis 23 (39.7) 2.51 (1.72e3.67)b 2.77 (1.66e4.63)b 2.35 (1.32e4.18)b
The unadjusted models are presented in Supplemental Table 1. The total numbers reflect the number of participants with complete outcome and covariate data in the final models.
Ref, reference group.
a Adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes, cardiac
disease, hypertension, kidney disease, or history of adverse pregnancy outcomes; b P<.05; c Severe perinatal morbidity and mortality index includes at least 1 of the following morbidities:
bronchopulmonary dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring transfusion, patent ductus arteriosus, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy
of prematurity, intrauterine or neonatal death, or neonatal intensive care unit stay of 7 days; d Composite maternal morbidity and mortality index includes at least 1 of the following morbidities:
third trimester vaginal bleeding, preterm labor, infections requiring antibiotics, maternal admission to the intensive care unit, referral to a higher level of care, or maternal death.
Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.
ajog.org OBSTETRICS Original ResearchStrengths and limitations of the
study
We used data from a large-scale, pro-
spective, multinational study that was
specifically conducted to assess the
symptoms and effects of COVID-19
during pregnancy on maternal and
neonatal outcomes when compared with
pregnant women not-diagnosed with
COVID-19 who were carefully enrolled
concomitantly tominimize selection bias.
Rigorous data monitoring was applied to
record severe morbidity markers
including preeclampsia and GH.
Our study has expected limitations.
The circumstances for the diagnosis ofmaternal infection changed over time,
from testing for severe symptoms of
COVID-19 only to screening on admis-
sion. Hence, we cannot exclude the pos-
sibility that women admitted to hospital
with a diagnosis of preeclampsia, or
those with risk factors, were more likely
to be tested for, or diagnosed with
COVID-19. Nor did we examine the
placentas of the women enrolled, which
might have helped to determine whether
the severityof infectioncorrelateswith the
extent of vasculitis or whether different
patterns of inflammation are seen in the 3
diagnostic groups.33However, this should
not reduce the impact of our resultsSEPTEMBER 2021 Ameribecause preeclampsia is a purely clinical
diagnosis. We assessed the association
between COVID-19 and preeclampsia in
symptomatic and asymptomatic women;
however, we could not conduct stratified
analyses according to the COVID-19
disease severity classification proposed
by the National Institutes of Health,
because we did not have the complete
information required by these relatively
recent criteria.31 Because this was an
observational study, the clinical manage-
ment of pregnancy complications, such
as COVID-19 and preeclampsia, was
based on local practice and therefore not
standardized. Finally, it is also possiblecan Journal of Obstetrics & Gynecology 289.e9
TABLE 6
Associations between gestational hypertension and COVID-19 diagnosis with adverse pregnancy and neonatal
outcomesa
Outcomes
n (%) with the
outcome All women Nulliparous Parous
Preterm delivery
No GH, no COVID-19 diagnosis 174 (13.2) Ref Ref Ref
No GH, with COVID-19 diagnosis 130 (21.5) 1.56 (1.27e1.92)b 1.76 (1.27e2.49)b 1.46 (1.12e1.90)b
GH, no COVID-19 diagnosis 17 (21.5) 1.43 (0.90e2.27) 1.62 (0.82e3.21) 1.27 (0.68e2.36)
GH, with COVID-19 diagnosis 22 (36.1) 2.34 (1.62e3.37)b 2.53 (1.47e4.37)b 2.11 (1.25e3.54)b
Small for gestational age
No GH, no COVID-19 diagnosis 156 (12.2) Ref Ref Ref
No GH, with COVID-19 diagnosis 74 (12.4) 1.08 (0.83e1.40) 1.25 (0.90e1.74) 0.90 (0.60e1.34)
GH, no COVID-19 diagnosis 17 (21.8) 2.06 (1.27e3.33)b 1.51 (0.77e2.98) 2.59 (1.30e5.15)b
GH, with COVID-19 diagnosis 12 (20.3) 1.74 (1.01e3.01)b 1.87 (1.00e3.51)c 1.37 (0.46e4.07)
Severe perinatal morbidity and mortality indexd
No GH, no COVID-19 diagnosis 102 (7.5) Ref Ref Ref
No GH, with COVID-19 diagnosis 103 (16.4) 2.14 (1.62e2.82)b 2.46 (1.60e3.77)b 1.88 (1.31e2.69)b
GH, no COVID-19 diagnosis 13 (15.9) 1.66 (0.83e3.31) 2.02 (0.78e5.24) 1.45 (0.55e3.80)
GH, with COVID-19 diagnosis 13 (20.6) 2.19 (1.24e3.87)b 2.15 (0.97e4.80)c 2.24 (1.00e5.02)c
Composite maternal morbidity and mortality indexe
No GH, no COVID-19 diagnosis 191 (14.5) Ref Ref Ref
No GH, with COVID-19 diagnosis 166 (27.2) 1.86 (1.54e2.23)b 1.73 (1.30e2.29)b 1.93 (1.51e2.47)b
GH, no COVID-19 diagnosis 14 (17.7) 1.16 (0.71e1.92) 0.97 (0.45e2.08) 1.25 (0.64e2.45)
GH, with COVID-19 diagnosis 17 (27.9) 1.80 (1.17e2.77)b 1.94 (1.13e3.35)b 1.38 (0.66e2.91)
Unadjusted models are shown in Supplemental Table 2. The total numbers reflect the number of participants with complete outcome and covariate data in the final models.
GH, gestational hypertension; Ref, reference group.
a Models adjusted for maternal age, previous parity (nulliparous vs parous) tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes,
cardiac disease, hypertension, kidney disease, or history of adverse pregnancy outcomes; b P<.05; c P<.1; d Severe perinatal morbidity and mortality index includes at least 1 of the following
morbidities: bronchopulmonary dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring transfusion, patent ductus arteriosus, intraventricular hemorrhage, necrotizing enterocolitis,
retinopathy of prematurity, intrauterine or neonatal death, or neonatal intensive care unit stay of 7 days; e Composite maternal morbidity and mortality index includes at least 1 of the following
morbidities: third trimester vaginal bleeding, preterm labor, infections requiring antibiotics, maternal admission to the intensive care unit, referral to a higher level of care, or maternal death.
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may have included a small number of
asymptomatic infected women who were
not identified, either because routine
testing was not available at that stage of
the pandemic or because they became
infected after they were included in the
not-diagnosed cohort. We do not
consider this a strong source of bias
because it would have led to more con-
servative estimates from the analyses us-
ing that group as reference.
Conclusions
Preeclampsia (and to a lesser degree
GH) is independently associated with289.e10 American Journal of Obstetrics & GynecCOVID-19 during pregnancy; both
conditions are associated independently
of and in an additive fashion with
increased risks for preterm birth, the
severe perinatal morbidity and mortal-
ity index, and composite adverse
maternal outcome. Hence, preeclamp-
sia (and GH) seem to be a strong risk
factor for SARS-CoV-2 infection and its
related complications. There was no
evidence to support that COVID-19 is
etiologically associated with pre-
eclampsia or GH. Clinicians caring for
women with preeclampsia should be
aware of the additional risks that
COVID-19 poses. nology SEPTEMBER 2021Acknowledgments
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For gestational age at delivery, stratified by gestational hypertension (GH) and COVID-19 diagnosis.
The blue curve indicates no GH, no COVID-19 diagnosis; the red curve indicates no GH with COVID-
19 diagnosis; the green curve indicates GH, no COVID-19 diagnosis; and the orange curve indicates
GH with COVID-19 diagnosis.
Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.
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SUPPLEMENTAL TABLE 1
Unadjusted associations between preeclampsia and COVID-19 diagnosis with adverse pregnancy and neonatal
outcomes
Adverse outcomes
n (%) with the
outcome All women Nulliparous Parous
Preterm delivery
No preeclampsia, no COVID-19 diagnosis 163 (12.2) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 119 (19.6) 1.60 (1.29e1.99)a 1.68 (1.17e2.41)a 1.53 (1.16e2.00)a
Preeclampsia, no COVID-19 diagnosis 28 (45.2) 3.69 (2.71e5.03)a 4.43 (2.87e6.86)a 3.19 (2.04e5.00)a
Preeclampsia, with COVID-19 diagnosis 33 (56.9) 4.65 (3.57e6.07)a 5.99 (4.18e8.58)a 3.69 (2.44e5.57)a
Small for gestational age
No preeclampsia, no COVID-19 diagnosis 162 (12.6) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 69 (11.6) 0.92 (0.70e1.21) 1.15 (0.81e1.62) 0.76 (0.50e1.17)
Preeclampsia, no COVID-19 diagnosis 11 (17.5) 1.39 (0.76e2.53) 1.63 (0.82e3.27) 0.94 (0.31e2.83)
Preeclampsia, with COVID-19 diagnosis 17 (29.3) 2.33 (1.53e3.55)a 2.48 (1.49e4.10)a 2.01 (0.97e4.15)b
Severe perinatal morbidity and mortality indexc
No preeclampsia, no COVID-19 diagnosis 100 (7.3) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 100 (15.9) 2.17 (1.64e2.86)a 2.53 (1.63e3.92)a 1.94 (1.36e2.78)a
Preeclampsia, no COVID-19 diagnosis 15 (22.4) 3.06 (1.83e5.13)a 3.63 (1.79e7.35)a 2.53 (1.17e5.45)a
Preeclampsia, with COVID-19 diagnosis 16 (27.1) 3.7 (2.32e5.91)a 4.35 (2.30e8.23)a 3.15 (1.57e6.36)a
Composite adverse maternal outcomed
No preeclampsia, no COVID-19 diagnosis 188 (14.1) Ref Ref Ref
No preeclampsia, with COVID-19 diagnosis 157 (25.8) 1.84 (1.53e2.22)a 1.78 (1.33e2.39)a 1.89 (1.48e2.42)a
Preeclampsia, no COVID-19 diagnosis 16 (25.8) 1.83 (1.17e2.84)a 2.17 (1.25e3.77)a 1.43 (0.67e3.00)
Preeclampsia, with COVID-19 diagnosis 23 (39.7) 2.81 (1.99e3.96)a 3.01 (1.91e4.74)a 2.56 (1.51e4.35)a
Ref, reference group.
a P<.05; b P<.1; c Severe perinatal morbidity and mortality index includes at least 1 of the following morbidities: bronchopulmonary dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia
requiring transfusion, patent ductus arteriosus, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, intrauterine or neonatal death, or neonatal intensive care unit stay
of 7 days; d Composite maternal morbidity and mortality index includes at least 1 of the following morbidities: third trimester vaginal bleeding, preterm labor, infections requiring antibiotics,
maternal admission to the intesive care unit, referral to a higher level of care, or maternal death.
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SUPPLEMENTAL TABLE 2
Unadjusted associations between gestational hypertensiona and COVID-19 diagnosis with adverse pregnancy and
neonatal outcomes
Adverse outcomes
n (%) with the
outcome All women Nulliparous Parous
Preterm delivery
No GH, no COVID-19 diagnosis 174 (13.2) Ref Ref Ref
No GH, with COVID-19 diagnosis 130 (21.5) 1.58 (1.26e1.99)b 1.72 (1.17e2.51)b 1.48 (1.11e1.97)b
GH, no COVID-19 diagnosis 17 (21.5) 2.5 (1.88e3.42)b 3.09 (2.00e4.79)b 2.18 (1.44e3.29)b
GH, with COVID-19 diagnosis 22 (36.1) 3.63 (2.79e4.73)b 4.18 (2.83e6.16)b 3.30 (2.29e4.76)b
Small for gestational age
No GH, no COVID-19 diagnosis 156 (12.2) Ref Ref Ref
No GH, with COVID-19 diagnosis 74 (12.4) 0.90 (0.68e1.21) 1.12 (0.77e1.63) 0.77 (0.50e1.20)
GH, no COVID-19 diagnosis 17 (21.8) 1.61 (1.08e2.39)b 1.57 (0.95e2.60)c 1.62 (0.86e3.05)
GH, with COVID-19 diagnosis 12 (20.3) 2.05 (1.41e2.99)b 2.11 (1.35e3.28)b 1.82 (0.92e3.59)c
Severe perinatal morbidity and mortality indexd
No GH, no COVID-19 diagnosis 102 (7.5) Ref Ref Ref
No GH, with COVID-19 diagnosis 103 (16.4) 2.30 (1.73e3.07)b 2.82 (1.80e4.45)b 2.00 (138e2.91)b
GH, no COVID-19 diagnosis 13 (15.9) 2.59 (1.66e4.03)b 2.90 (1.52e5.56)b 2.33 (1.26e4.31)b
GH, with COVID-19 diagnosis 13 (20.6) 3.04 (1.97e4.68)b 2.98 (1.59e5.61)b 3.13 (1.72e5.68)b
Composite maternal morbidity and mortality indexe
No GH, no COVID-19 diagnosis 191 (14.5) Ref Ref Ref
No GH, with COVID-19 diagnosis 166 (27.2) 1.89 (1.55e2.29)b 1.78 (1.31e2.42)b 1.96 (1.52e2.52)b
GH, no COVID-19 diagnosis 14 (17.7) 1.46 (1.01e2.09)b 1.67 (1.03e2.71)b 1.26 (0.73e2.17)
GH, with COVID-19 diagnosis 17 (27.9) 2.22 (1.62e3.03)b 2.50 (1.67e3.75)b 1.88 (1.13e3.10)b
GH, gestational hypertension; Ref, reference group.
a Includes preeclampsia or gestational hypertension; b P<.05; c P<.1; d Severe perinatal morbidity and mortality index includes at least 1 of the following morbidities: bronchopulmonary dysplasia,
hypoxic-ischemic encephalopathy, sepsis, anemia requiring transfusion, patent ductus arteriosus, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, intrauterine or
neonatal death, or neonatal intensive care unit stay of7 days; e Composite maternal morbidity and mortality index includes at least 1 of the following morbidities: third trimester vaginal bleeding,
preterm labor, infections requiring antibiotics, maternal admission to the intensive care unit, referral to a higher level of care, or maternal death.
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SUPPLEMENTAL TABLE 3
Sensitivity analyses incorporating study site in associations between COVID-19 diagnosis and preeclampsiaa
Model All women Nulliparous Parous
Primary model 1.77 (1.25e2.52)b 1.89 (1.17e3.05)b 1.64 (0.99e2.73)c
Adjust for study site 1.87 (1.33e2.61)b 1.95 (1.21e3.15)b 1.95 (1.21e3.15)b
Mixed-effects with random intercept 1.85 (1.36e2.53)b 1.90 (1.53e2.37)b 1.88 (1.06e3.35)b
a Models adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes,
cardiac disease, hypertension, kidney disease, or adverse pregnancy outcomes and country of enrollment; b P<.05; c P<.1.
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